New drug VIS171 enters human testing for lupus, hair loss, and kidney disease
NCT ID NCT06799520
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This early-stage trial tests a new drug, VIS171, in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care, and are followed for up to a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Visterra Investigational Site
RECRUITINGSofia, 1404, Bulgaria
-
Visterra Investigational Site
RECRUITINGChisinau, MD-2025, Moldova
-
Visterra Investigational Site
RECRUITINGBucharest, 11658, Romania
-
Visterra Investigational Site
RECRUITINGCluj-Napoca, 40006, Romania
-
Visterra Investigational Site
NOT_YET_RECRUITINGBarcelona, 8035, Spain
-
Visterra Investigational Site
NOT_YET_RECRUITINGGranada, 18014, Spain
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VIS171
What this could lead to
If safe and effective, VIS171 could become a new treatment option for certain autoimmune diseases like lupus and alopecia areata.
What could go wrong
This is a very early Phase 1 trial with only 30 people, focused on safety. It is too soon to know if VIS171 works, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.